BrainStorm Cell Therapeutics Public
BrainStorm Cell Therapeutics is a biotechnology company that specializes in developing innovative autologous stem cell therapies for neurodegenerative diseases such as ALS, MS, and PD. Their proprietary technology, NurOwn™, allows for the propagation and differentiation of autologous MSCs into NTF-secreting cells, which can be transplanted near the site of damage. The company is currently conducting a Phase IIa ALS clinical trial at the Hadassah University Medical Center in Jerusalem, with plans to begin a Phase II trial in the USA pending FDA approval. BrainStorm has received Orphan Drug designation from the FDA and has published over 20 scientific articles demonstrating the efficacy of their neuron mechanism.
%20.jpg)
Funding Status:
N/A
Technology:
Regenerative Medicine
Number Of Exists:
Grant
Investors Number:
5
Employee Number:
38
Industry:
Stem Cells (Regenerative Medicine)
Headquarters:
New York, New York, United States
Total Funding:
$51.6M
Last Funding Type:
Grant
Founded Date:
6-26
Investment Stage:
N/A
Estimated Revenue:
Less than $1M
Investor Type:
Company